[Duloxetine receives positive recommendation by the Scientific Committee of EMEA for treatment of depression].
D018759:Adrenergic Uptake Inhibitors / Q000008:administration & dosage*; D000928:Antidepressive Agents / Q000008:administration & dosage*; D003865:Major Depressive Disorder / Q000188:drug therapy / Q000451:nursing*; D003929:Diabetic Neuropathies / Q000188:drug therapy / Q000451:nursing; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D000068736:Duloxetine Hydrochloride; D005060:Europe; D006801:Humans; D010606:Pharmacy and Therapeutics Committee / Q000331:legislation & jurisprudence; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage*; D013876:Thiophenes / Q000008:administration & dosage*; D014550:Urinary Incontinence, Stress / Q000188:drug therapy / Q000451:nursing
D018759:Adrenergic Uptake Inhibitors; D000928:Antidepressive Agents; D000068736:Duloxetine Hydrochloride; D017367:Selective Serotonin Reuptake Inhibitors; D013876:Thiophenes